New research presented on photodisinfection
20 September 2022
Ondine Biomedical Inc.
("Ondine Biomedical", "Ondine" or the "Company")
New research shows photodisinfection successfully eradicates pathogens associated with replacement joint infections
A research team in Zurich, Switzerland has presented results from an in vitro study showing that photodisinfection achieved >99.99% eradication (4-7 log10 kill) of the key pathogens in biofilms associated with implantable joint infections, with no reported regrowth. These results were presented at the recent Swiss Society for Microbiology (SSM) Annual Congress 2022 in Lausanne, Switzerland.
Periprosthetic joint infections (PJIs) are typically extremely hard to treat,[i] but this new research finds that photodisinfection may be an exciting new treatment approach. The research team, lead by PD Dr. med. Yvonne Achermann is planning further clinical research on the safety and efficacy of the PJI treatment.
PJIs are most commonly caused by the bacteria Staphylococcus aureus (S. aureus).[ii] Patients undergoing major surgeries like hip or knee replacements face the risk of life-threatening infections - with the majority of these related to the patients' own microflora. In the US alone, the annual cost of treating PJIs is estimated at $1.62 billion.[iii]
Lead author, Julia Prinz commented: "PJIs are difficult to treat due to biofilm formation on implant surfaces. These infections often require removal or exchange of prostheses and long-duration antibiotic treatment. We found that photodisinfection effectively eradicated important pathogens involved in PJI - whether in planktonic form or biofilms grown on commonly used arthroplasty materials - and without harming the prosthetic materials."
Photodisinfection, also known as antimicrobial photodynamic therapy (aPDT), is a broad-spectrum antimicrobial treatment which uses non-thermal light to activate a photosensitive agent. In a few minutes, this light-based therapy destroys pathogens through an oxidative burst without harming the implant or human tissue. Importantly, photodisinfection is effective against drug-resistant pathogens and does not cause resistance-formation, both distinct advantages over antibiotics.
The photodisinfection technology used in the study was provided by Canadian life sciences company Ondine Biomedical, who recently announced results from its US Phase 2 trial showing that nasal photodisinfection eliminated or significantly decreased nasal S. aureus in 92% of pre-surgical patients.[iv]
The poster entitled "In vitro methylene blue based antimicrobial photodynamic therapy for effective biofilm eradication in periprosthetic joint infection" was presented by Julia Prinz at the SSM Annual Congress 2022 in Lausanne, Switzerland (all authors: Julia Prinz, Marianne Wink, Sonja Neuhaus, Markus C. Grob, Heinrich Walt, Philipp P. Bosshard, Yvonne Achermann).
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products include therapies for a variety of medical indications such as nasal disinfection, sinusitis, ventilator-associated pneumonia, burns, and other indications. Ondine's nasal photodisinfection technology is approved in several jurisdictions under the brand name Steriwave™. It has been awarded the CE mark and, in the US, has been granted Qualified Infectious Disease Product designation and Fast Track status in the US by the FDA.
For further information, please visit: www.ondinebio.com or contact:
Ondine Biomedical Inc.:
Angelika Vance
Telephone: +1 604 838-2702 avance@ondinebio.com
Department of Dermatology, University Hospital Zurich, University of Zurich, Switzerland:
Yvonne Achermann
Email: yvonne.achermann@usz.ch
Julia Prinz
Email: julia.prinz@usz.ch
Media Contact:
Simon Vane Percy
Telephone: +44 (0)7710005910 Email: simon@vanepercy.com / amanda@vanepercy.com
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund